31Jul
31Jul
Dechra Purchases Veterinary Insulin Programs from Akston Biosciences
Dechra Limited, a global specialist veterinary pharmaceuticals and related products business, and Akston Biosciences Corporation, dedicated to accelerating the biologics revolution in Animal Health, today announces Dechra’s purchase of all Akston’s interests in the companies’ dog and cat long-acting insulin programs. Dechra’s purchase gives it ownership of the intellectual property and rights for the development, manufacturing, and worldwide commercialization of both programs. For its interests, Akston receives an upfront cash payment, fees to support technology transfer, and near-term milestone payments...
26Jul
Archer Roose and Cornell University Revolutionize the Canned Wine Category With Award-Winning Research
Archer Roose, a trailblazer in the premium canned wine sector, proudly announces its collaboration with Cornell University's Food Science Department in a groundbreaking study that sets a new benchmark for the industry. The research, titled "Hydrogen Sulfide Formation in Canned Wines: Variation Among Can Sources," has been honored with the prestigious Best Oenology Paper award by the American Journal of Enology and Viticulture (AJEV). Since 2019, Archer Roose has been at the forefront of innovation, partnering with Cornell University to...
24Jul
We are waging war against the dominance of plastic: Rahul Singh, EcoSoul Home
In a world increasingly aware of the environmental impact of everyday products, EcoSoul Home has emerged as a leader in providing eco-friendly home essentials. Co-founded by Rahul Singh and Arvind Ganeshan, EcoSoul Home is on a mission to challenge the dominance of plastic and tree-based products in the home essentials market. The brand has quickly expanded its reach, offering a sustainable alternative to conventional products across the globe. Read more >>
24Jul
L3 Networks Partners With Wasabi Technologies to Deliver Secure and Scalable Offsite Backup Storage Solutions
Bringing an extra measure of confidence to digital storage backup and restoration, from security to speed to scalability, managed service provider L3 Networks has finalized a partnership with Wasabi Technologies, the hot cloud storage company. This collaboration positions Wasabi as the company’s primary provider of offsite backup storage, enhancing the safety, efficiency, and dependability of L3’s data management services. Read more >>
20Jul
KnipBio Inc. welcomes new CEO
KnipBio, a leading precision fermentation biotechnology company, today announced new CEO, Caitlin Wege. The Board of Directors of KnipBio is pleased to announce the appointment of Caitlin Wege as its new Chief Executive Officer, effective immediately. Caitlin brings over 15 years of experience working with companies across various industries, with a sharp focus on operational excellence and strategic growth. She has a proven track record of leading organizational change that aligns with long-term goals. Read more >>
19Jul
Wasabi Technologies Now Available in Climb Channel Solutions’ Portfolio of GSA Offerings
Climb Channel Solutions, an international specialty technology distributor and wholly owned subsidiary of Climb Global Solutions, Inc. (NASDAQ: CLMB) announced the expansion of their GSA IT-70 Contract (47QTCA19D008G) with the addition of Wasabi Technologies, a market leader in Hot Cloud Storage and strategic partner of Climb since 2020. As part of its GSA solutions, Climb will be offering Wasabi hot cloud storage, which delivers predictably priced, highly performant, and secure cloud object storage for customers that require an in-depth defense...
13Jul
D&D Pharmatech’s US unit to work with NIH, Johns Hopkins for Parkinson’s research
Neuraly, a U.S. subsidiary of D&D Pharmatech, has announced a collaboration with the National Institute on Aging (NIA) under the National Institutes of Health (NIH) and Johns Hopkins University School of Medicine to advance biomarker research using serum samples from patients involved in the phase 2 clinical trial of NLY01, a treatment for Parkinson's disease. NLY01, a long-acting GLP-1 receptor agonist, is being developed as a therapeutic for neurodegenerative diseases, including Parkinson's disease. he drug recently completed a global phase...
03Jul